Release date: 2016-10-12 On October 11, Sansheng Pharmaceutical announced that its wholly-owned subsidiary Hong Kong Sansheng and AstraZeneca signed an exclusive license agreement to acquire four products in the latter's diabetes field with an exclusive license period of 20 years. The four products are: Byetta (common name is exenatide injection), Bydureon (exenatide sustained release agent), Bydureon dual chamber pen (injection pen), Bydureon autoinjector (autoinjector). According to the agreement, AstraZeneca granted Sansheng Pharmaceutical exclusive rights to commercialize the above four products in China. Sansheng Pharmaceutical will pay AstraZeneca an advance payment of USD 50 million and a maximum installment amount of USD 50 million. The total license price is 1 Billion dollars, about 670 million yuan. In addition, Sansheng Pharmaceutical will pay AstraZeneca a pre-approved purchase price for the licensed product under the terms of the exclusive license agreement. According to previous reports, AstraZeneca has been selling some businesses with a transaction amount of up to $2 billion. The trade between AstraZeneca and Sansheng Pharmaceuticals is the third in the near future: On October 7, AstraZeneca sold its nose spray Rhinocort Aqua's US interest to Johnson & Johnson for US$330 million, which will cause severe ulceration. The enteritis drug was sold to Aerjian for $1.3 billion. Two products, four easy to master This time, Sansheng Pharmaceutical acquired two diabetes products, and the name of Byetta in China is Baibida. The product was jointly developed by AstraZeneca and Lilly in 1995 and was approved by the FDA in 2005. It was approved by the CFDA in August 2009. Peripheral is a GLP-1 receptor agonist injection that is used to improve glycemic control in patients with type 2 diabetes and requires daily injections twice. The product's 2013 sales were $606 million. Bydureon can be called the "upgraded version" of Baeida, a sustained-release preparation of exenatide, which is administered subcutaneously once a week for the control of type 2 diabetes. The product was approved by the FDA in 2012 and submitted for listing in China in May 2016. The product sold globally in 2013 at $298 million. In the field of diabetes, Baeida and Bydureon are two highly regarded products, and there are many stories about them. Things to start from 2007, this year, Bristol-Myers Squibb and AstraZeneca established a diabetes alliance to develop drugs for the treatment of type 2 diabetes. At that time, the alliance really brought attention and new products to the two companies. It successfully listed the oral drugs saxagliptin tablets (Anlisze) and kombiglyze. Perfida and Bydureon were acquired by the 2012 Diabetes Alliance through the acquisition of American Anylin. Prior to this, the two products were commercialized by Lilly. At that time, both BMS and AstraZeneca had high hopes for these two diabetes products in China. At that time, BMS and AstraZeneca were jointly responsible for the sales and marketing of Baxter in the Chinese market. By 2013, the fate of Perfida and Bydureon has changed. This one, the six-year diabetes alliance gradually declined, and at the end of the year, BMS made a price of 4.1 billion US dollars, and sold its share in the diabetes alliance to AstraZeneca, which obtained diabetes drugs including An Lize and Bai Seda. Global exclusive ownership of R&D, production and commercialization of products such as Bydureon. This time, AstraZeneca has licensed these two products to Sansheng Pharmaceutical, which is the fourth time to replace the market operation. Although the competition in the diabetes market is fierce, the market potential is obvious to all. As one of the countries with the largest number of patients, the potential base of diabetes in China is huge. This is also one of the driving forces of many multinational pharmaceutical companies that have announced their entry into the diabetes field. It is also the focus of Sansheng Pharmaceutical, a Chinese biopharmaceutical company. From the point of view of product strength and global sales, Baibida and its long-acting Bydureon have a good performance in the field of diabetes. However, in the Chinese market, there is still room for the market potential. In 2014, Perfida's total revenue in China was approximately 75 million yuan, and its sales in China in 2015 were 98 million yuan. Compared with their performance in the world, in China, these two products are still in the market introduction period. At this time, a team more familiar with the Chinese market needs to be in operation. The chairman of Sansheng Pharmaceuticals told E-pharmacy managers. He thinks Sansheng Pharmaceutical is the more suitable team. "I think AstraZeneca's strategy is right. The growth of these two products will be better on our platform." Sansheng will integrate the Baizhida team Sanhua Pharmaceutical announced that the strategic cooperation with AstraZeneca has enabled the Sansheng Group's product line to expand vigorously and penetrate the market in the field of diabetes, establishing a new product for Baiqingda and long-acting Bydureon. A professional team in the field of diabetes. The Board believes that with the excellent management team and rich management experience of Sansheng Group's marketing, this cooperation will bring continuous growth of business income and profit for Sansheng in the future. As we all know, in the past years, Sansheng Pharmaceutical has been the mainstay of kidney disease, cancer, and immunity. However, in the view of Yu Jing, the areas that Sansheng had previously focused on are also chronic disease treatments. In the long-term goal, metabolic diseases represented by diabetes will also be one of the focuses of attention. These two are obtained by AstraZeneca. Products are carried along this goal. For the next marketing and integration. Sansheng announced that as part of the commercialization of licensed products in China, the licensee agrees that its or its affiliates will employ Axlikon affiliates to engage in marketing licenses for certain marketing employees in China to join Sansheng, exclusively engaged in licensed products. Commercialization activities. In short, the original AstraZeneca marketing team will be integrated into the Sansheng Group. It is also worth mentioning that although Sansheng now has various product lines such as biopharmaceuticals and chemical drugs, there is a unified sales team for sales. This year, Xiao Weihong, the CEO of the original Haizheng Pfizer, who had experience in sales of multinational companies, was hired this year. As the COO of Sansheng Pharmaceutical, he is in charge of marketing and introduces the advance layout for the current AstraZeneca original team. In this regard, Yan Jing said that Sansheng’s sales experience in the local market over the past years is more abundant than AstraZeneca. AstraZeneca also agrees, and said that with the extensive experience of Sansheng Pharmaceutical in biotechnology and injection injection, this strategic cooperation will enable more patients in China to benefit from the innovative treatment of Baida and the upcoming Bydureon. The program also enables AstraZeneca to focus more on oral diabetes drugs. Source: E drug manager Microbiotic
Microbiotic, Nitazoxanide Antibiotic,Ceftiofur Sodium,Ceftiofur Sodium Sterile Powder,Imatinib Mesylate Powder,
Henrikang Biotech is specialized in Research, Analysis, Production, Application, Process and Sales. We insist in innovation and produce Microbiotic, Nitazoxanide Antibiotic,Ceftiofur Sodium,Ceftiofur Sodium Sterile Powder,Imatinib Mesylate Powder Xi'an Henrikang Biotech Co.,Ltd , https://www.henruikangbio.com
high quality products. Our main products are Top quality APIs Raw Material, Best price Herbal Extract, High Quality Sarms Body
Building, Wholesale price Cosmetic Raw Material, Professional and reliable Veterinary raw Material, natural product Food Supplement,
Loss Weight Powder, research and so on.
Now we have 3 GMP standard workshop, Meanwhile, Healthcare Product factory is equipped with the researching and quality
inspection centre, with strong technology research and development strength. Blood Pressure raw powder have 3 sales departments
over 30 people to sell our products all over the world. For customer`s requirements, OEM / ODM service is available. Such as customized
bottled capsules, blister, etc.Organic Hemp Protein have excellent quality.The best-selling product is Glutathione Oral Solution.Let
customers have a consistent praise of the product is Humectants Cosmetic Raw.Henrikang adhere to the concept of [Green, Natural
and Health", sincerely hope to strengthen exchanges and cooperation with you.